<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02773238</url>
  </required_header>
  <id_info>
    <org_study_id>9599</org_study_id>
    <secondary_id>NCI-2016-00543</secondary_id>
    <secondary_id>9599</secondary_id>
    <secondary_id>R01CA204301</secondary_id>
    <secondary_id>RG3116002</secondary_id>
    <nct_id>NCT02773238</nct_id>
  </id_info>
  <brief_title>FLARE RT for Patients With Stage IIB-IIIB Non-small Cell Lung Cancer: Personalizing Radiation Therapy Using PET/CT and SPECT/CT Imaging</brief_title>
  <official_title>Personalized Radiation Therapy Through Functional Lung Avoidance and Response-Adaptive Dose Escalation: Utilizing Multimodal Molecular Imaging to Improve the Therapeutic Ratio (FLARE RT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well positron emission tomography (PET)/computed tomography&#xD;
      (CT) and single positron emission computed tomography (SPECT)/CT imaging works in improving&#xD;
      radiation therapy treatment in patients with stage IIB-IIIB non-small cell lung cancer.&#xD;
      PET/CT imaging mid-way through treatment may be able to accurately show how well radiation&#xD;
      therapy and chemotherapy are working. SPECT/CT imaging may be able to tell which parts of the&#xD;
      lung tissue are healthier than others. Based on the result of the imaging, treatment&#xD;
      adjustments may be made to the radiation therapy to improve survival and decrease toxicity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To test the superiority of 2 year (yr) overall survival (OS) in the functional lung&#xD;
      avoidance and response-adaptive dose escalation (FLARE) radiation therapy (RT) patient cohort&#xD;
      over the 60 gray (Gy) cohort of Radiation Therapy Oncology Group (RTOG) 0617 (57% 2yr OS) for&#xD;
      historical control.&#xD;
&#xD;
      SECONDARY OBJECTIVE:&#xD;
&#xD;
      I. Common Terminology Criteria for Adverse Events (CTCAE) version (v) 4 grade 2 or higher&#xD;
      pneumonitis incidence from FLARE RT compared to historical controls (non-inferiority test).&#xD;
&#xD;
      II. 1 yr local control, progression-free survival, and pulmonary function test decline.&#xD;
&#xD;
      III. Identification of baseline fludeoxyglucose (FDG) PET/CT and mid-treatment FDG PET/CT&#xD;
      imaging biomarkers for predicting patient survival.&#xD;
&#xD;
      IV. Identification of baseline perfusion SPECT/CT imaging biomarkers for predicting grade&#xD;
      (G)2+ pneumonitis and pulmonary function tests (PFT) decline.&#xD;
&#xD;
      V. Collection of plasma and urine samples for future correlative studies between imaging&#xD;
      biomarkers and cytokine biomarkers of radiation response in both tumor and normal tissue.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of radiation therapy.&#xD;
&#xD;
      Patients undergo functional avoidance radiation therapy during weeks 1-3. Patients undergo&#xD;
      fludeoxyglucose F-18 FDG PET/CT at baseline, 3 weeks, and 3 months post-radiation therapy and&#xD;
      undergo technetium Tc-99m albumin aggregated (99mTc-MAA) and technetium Tc-99m sulfur colloid&#xD;
      SPECT/CT radiation therapy at baseline and 3 months post-radiation therapy. Baseline PET/CT&#xD;
      must be performed at University of Washington Medical Center/Seattle Cancer Care Alliance and&#xD;
      be within one month of treatment start, therefore some patients may need to repeat a baseline&#xD;
      PET/CT if their PET/CT is from an outside institution or &gt; 1 month old. Patients not&#xD;
      responding to treatment at 3 weeks, will receive an increased daily radiation therapy dosage.&#xD;
&#xD;
      After completion of study treatment, patients are followed up for 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 20, 2016</start_date>
  <completion_date type="Anticipated">December 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival (OS) rate</measure>
    <time_frame>At 2 years</time_frame>
    <description>Will be compared to the 60 Gy cohort of Radiation Therapy Oncology Group 0617 for historical control. A one sample proportionality test using all patients who complete either functional lung avoidance and response-adaptive dose escalation (FLARE) radiation therapy (RT) treatment arm (standard dose arm in responders + dose escalation arm in non-responders) will be performed. Interim and final statistical analyses of OS will consist of Kaplan-Meier estimation and cox proportional hazard regression.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of pulmonary toxicity defined as Common Terminology Criteria for Adverse Events version 4 grade 2 or higher pneumonitis</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>Will be compared between patients receiving FLARE RT and historical rates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local-regional control as defined by Response Evaluation Criteria In Solid Tumors (RECIST) criteria</measure>
    <time_frame>At 1 year</time_frame>
    <description>Intrathoracic control of lung tumors assessed by post-radiotherapy computed tomography. Control will be defined as lack of progressive disease as defined by RECIST criteria. Interim and final statistical analyses of local control will consist of Kaplan-Meier estimation and cox proportional hazard regression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Interim and final statistical analyses of local control will consist of Kaplan-Meier estimation and cox proportional hazard regression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pulmonary function-forced expiratory volume in 1 second (FEV1)</measure>
    <time_frame>Baseline to 3 months post-radiation therapy</time_frame>
    <description>Pulmonary function tests (FEV1, liters) will be performed and change over time will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pulmonary function (diffusing capacity of the lungs for carbon monoxide [DLCO])</measure>
    <time_frame>Baseline to 3 months post-radiation therapy</time_frame>
    <description>Pulmonary function tests (DLCO, % predicted) will be performed and change over time will be evaluated.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Stage IIB Lung Non-Small Cell Carcinoma AJCC v7</condition>
  <condition>Stage IIIA Lung Non-Small Cell Cancer AJCC v7</condition>
  <condition>Stage IIIB Lung Non-Small Cell Cancer AJCC v7</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo functional avoidance radiation therapy during weeks 1-3. Patients undergo fludeoxyglucose F-18 FDG PET/CT at baseline, 3 weeks, and 3 months post-radiation therapy and undergo technetium Tc-99m albumin aggregated (99mTc-MAA) and technetium Tc-99m sulfur colloid SPECT/CT radiation therapy at baseline and 3 months post-radiation therapy. Baseline PET/CT must be performed at University of Washington Medical Center/Seattle Cancer Care Alliance and be within one month of treatment start, therefore some patients may need to repeat a baseline PET/CT if their PET/CT is from an outside institution or &gt; 1 month old. Patients not responding to treatment at 3 weeks, will receive an increased daily radiation therapy dosage.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Computed Tomography</intervention_name>
    <description>Undergo FDG PET/CT</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>CAT</other_name>
    <other_name>CAT Scan</other_name>
    <other_name>Computerized Axial Tomography</other_name>
    <other_name>computerized tomography</other_name>
    <other_name>CT</other_name>
    <other_name>CT SCAN</other_name>
    <other_name>tomography</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Computed Tomography</intervention_name>
    <description>Undergo Tc-99m MAA or Tc-99m DTPA</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>CAT</other_name>
    <other_name>CAT Scan</other_name>
    <other_name>Computerized Axial Tomography</other_name>
    <other_name>computerized tomography</other_name>
    <other_name>CT</other_name>
    <other_name>CT SCAN</other_name>
    <other_name>tomography</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Fludeoxyglucose F-18</intervention_name>
    <description>Undergo FDG PET/CT</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>18FDG</other_name>
    <other_name>FDG</other_name>
    <other_name>fludeoxyglucose F 18</other_name>
    <other_name>Fludeoxyglucose F18</other_name>
    <other_name>Fluorine-18 2-Fluoro-2-deoxy-D-Glucose</other_name>
    <other_name>Fluorodeoxyglucose F18</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Positron Emission Tomography</intervention_name>
    <description>Undergo FDG PET/CT</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Medical Imaging, Positron Emission Tomography</other_name>
    <other_name>PET</other_name>
    <other_name>PET Scan</other_name>
    <other_name>Positron Emission Tomography Scan</other_name>
    <other_name>Positron-Emission Tomography</other_name>
    <other_name>proton magnetic resonance spectroscopic imaging</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation Therapy</intervention_name>
    <description>Undergo functional avoidance radiation therapy</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Cancer Radiotherapy</other_name>
    <other_name>Irradiate</other_name>
    <other_name>Irradiated</other_name>
    <other_name>irradiation</other_name>
    <other_name>RADIATION</other_name>
    <other_name>Radiotherapeutics</other_name>
    <other_name>radiotherapy</other_name>
    <other_name>RT</other_name>
    <other_name>Therapy, Radiation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Single Photon Emission Computed Tomography</intervention_name>
    <description>Undergo Tc-99m MAA or Tc-99m Undergo Tc-99m sulfur colloid SPECT/CT</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Medical Imaging, Single Photon Emission Computed Tomography</other_name>
    <other_name>Single Photon Emission Tomography</other_name>
    <other_name>single-photon emission computed tomography</other_name>
    <other_name>SPECT</other_name>
    <other_name>SPECT imaging</other_name>
    <other_name>SPECT SCAN</other_name>
    <other_name>SPET</other_name>
    <other_name>tomography, emission computed, single photon</other_name>
    <other_name>Tomography, Emission-Computed, Single-Photon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Technetium Tc-99m Albumin Aggregated</intervention_name>
    <description>Undergo Tc-99m MAA SPECT/CT</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Tc 99m-labeled MAA</other_name>
    <other_name>Technetium Tc 99m-Labeled Macroaggregated Albumin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Technetium Tc-99m Sulfur Colloid</intervention_name>
    <description>Undergo Tc-99m sulfur colloid</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Tc 99m sulfur colloid</other_name>
    <other_name>Tc-99m SC</other_name>
    <other_name>technetium Tc 99m sulfur colloid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathologically proven (either histologic or cytologic) diagnosis of stage IIB-IIIB&#xD;
             non-small cell lung cancer (NSCLC); according to American Joint Committee on Cancer&#xD;
             (AJCC) staging, 7th edition&#xD;
&#xD;
               -  Staging workup must include: brain imaging (CT head or magnetic resonance imaging&#xD;
                  [MRI] brain) and PET/CT&#xD;
&#xD;
               -  Pleural effusions must have cytology to rule out malignant involvement unless too&#xD;
                  small to undergo thoracentesis per radiology&#xD;
&#xD;
          -  Patients must be considered unresectable or inoperable&#xD;
&#xD;
          -  Patient must not have received prior radiation for this lung cancer&#xD;
&#xD;
          -  Patients must be having concurrent chemotherapy&#xD;
&#xD;
          -  Nodal recurrences can be treated on this protocol but prior curative surgery for lung&#xD;
             cancer must have been at least 6 months prior to the nodal recurrence&#xD;
&#xD;
          -  Patients must have measurable or evaluable disease that is FDG avid with standardized&#xD;
             uptake value (SUV) &gt; 3 on PET/CT&#xD;
&#xD;
          -  Zubrod performance status 0-1&#xD;
&#xD;
          -  PFTs including forced expiratory volume in 1 second (FEV1) within 26 weeks prior to&#xD;
             registration; for FEV1, the best value obtained pre- or post-bronchodilator must be &gt;=&#xD;
             0.8 liters/second or &gt;= 50% predicted&#xD;
&#xD;
          -  Blood cell count (CBC)/differential obtained within 8 weeks prior to registration on&#xD;
             study&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt;= 1,800 cells/mm^3&#xD;
&#xD;
          -  Platelets &gt;= 100,000 cells/mm^3&#xD;
&#xD;
          -  Hemoglobin &gt;= 10.0 g/dl (Note: The use of transfusion or other intervention to achieve&#xD;
             hemoglobin (Hgb) &gt;= 10.0 g/dl is acceptable)&#xD;
&#xD;
          -  Serum creatinine within normal institutional limits or creatinine clearance &gt;= 40&#xD;
             ml/min&#xD;
&#xD;
          -  Bilirubin must be within or below normal institutional limits&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) &lt; 2.5 x the&#xD;
             institutional upper limit of normal (IULN)&#xD;
&#xD;
          -  Patient must sign study specific informed consent prior to study entry&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  &gt; 10% unintentional weight loss within the past month&#xD;
&#xD;
          -  Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free&#xD;
             for a minimum of 3 years; non-invasive conditions such as carcinoma in situ of the&#xD;
             breast, oral cavity, or cervix are all permissible&#xD;
&#xD;
          -  Prior radiotherapy to the region of the study cancer that would result in overlap of&#xD;
             radiation therapy fields&#xD;
&#xD;
          -  Pregnancy or women of childbearing potential and men who are sexually active and not&#xD;
             willing/able to use medically acceptable forms of contraception&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jing Zeng</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SCCA Proton Therapy Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 28, 2016</study_first_submitted>
  <study_first_submitted_qc>May 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2016</study_first_posted>
  <last_update_submitted>July 7, 2021</last_update_submitted>
  <last_update_submitted_qc>July 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deoxyglucose</mesh_term>
    <mesh_term>Fluorodeoxyglucose F18</mesh_term>
    <mesh_term>Technetium Tc 99m Sulfur Colloid</mesh_term>
    <mesh_term>Technetium Tc 99m Aggregated Albumin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

